RLF 주식 개요 릴리프 테라퓨틱스 홀딩 SA는 스위스, 유럽, 북미 및 전 세계에서 희귀 대사, 피부과, 폐 질환 치료를 위한 새로운 특허 보호 제품을 식별, 개발 및 상업화하는 데 주력하는 바이오 제약 회사입니다. 자세한 내용
생각, 링크 및 회사 내러티브를 캡처하세요.
Relief Therapeutics Holding SA 경쟁사 가격 내역 및 성능
다음에 대한 주가 최고가, 최저가 및 변동 요약 Relief Therapeutics Holding 과거 주가 현재 주가 CHF 4.45 52주 최고치 CHF 7.60 52주 최저치 CHF 1.06 베타 -14.7 1개월 변경 -12.75% 3개월 변경 사항 72.48% 1년 변경 사항 123.62% 3년 변화 -82.11% 5년 변화 827.08% IPO 이후 변화 -77.75%
최근 뉴스 및 업데이트
Relief Therapeutics Holding SA Announces Final Readout of PKU GOLIKE Clinical Trial Dec 16
Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa Nov 11 Renexxion, LLC signed a letter of intent to acquire Relief Therapeutics Holding SA (SWX:RLF) in a reverse merger transaction valued at $260 million. Nov 05
Relief Therapeutics Reports New Study Results for RLF-OD032 and Files Provisional Patents Oct 25
We Think Relief Therapeutics Holding (VTX:RLF) Can Easily Afford To Drive Business Growth Oct 09
Relief Therapeutics Holding SA Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa Oct 08 더 많은 업데이트 보기
Relief Therapeutics Holding SA Announces Final Readout of PKU GOLIKE Clinical Trial Dec 16
Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa Nov 11 Renexxion, LLC signed a letter of intent to acquire Relief Therapeutics Holding SA (SWX:RLF) in a reverse merger transaction valued at $260 million. Nov 05
Relief Therapeutics Reports New Study Results for RLF-OD032 and Files Provisional Patents Oct 25
We Think Relief Therapeutics Holding (VTX:RLF) Can Easily Afford To Drive Business Growth Oct 09
Relief Therapeutics Holding SA Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa Oct 08
Relief Therapeutics Holding SA Reports Positive Results from RLF-OD032 Proof-of-Concept Clinical Study for Phenylketonuria Oct 04
Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-Of-Concept Study; Topline Results Expected in October 2024 Sep 18
New minor risk - Shareholder dilution Sep 15
Relief Therapeutics Holding SA's (VTX:RLF) Share Price Boosted 52% But Its Business Prospects Need A Lift Too Sep 03
Relief Therapeutics Holding SA (VTX:RLF) Surges 52% Yet Its Low P/S Is No Reason For Excitement Sep 03
Relief Therapeutics Holding SA Announces PKU GOLIKE Study Results Presentation at SSIEM 2024 Sep 02
Relief Therapeutics Holding SA to Report First Half, 2024 Results on Aug 30, 2024 Jun 28 Relief Therapeutics Holding Announces Michelle Lock Will Not Stand for Re-Election as A Member of the Board of Directors
Relief Therapeutics Holding SA, Annual General Meeting, Jun 27, 2024 May 31 Relief Therapeutics Announces Executive Changes
New major risk - Share price stability May 07
Full year 2023 earnings released: CHF8.35 loss per share (vs CHF4.81 loss in FY 2022) May 02
New minor risk - Financial data availability Apr 02 Relief Therapeutics Holding SA announced that it expects to receive CHF 50 million in funding from Global Emerging Markets and another investor Feb 28
Less than half of directors are independent Nov 28
Relief Therapeutics Holding Sa Announces CEO Changes Nov 22
First half 2023 earnings released: CHF5.10 loss per share (vs CHF2.55 loss in 1H 2022) Sep 19
New major risk - Financial position Sep 17 Relief Therapeutics Holding AG announced that it expects to receive CHF 5 million in funding Jun 17
Relief Therapeutics Holding AG, Annual General Meeting, Jun 20, 2023 May 26
Health Check: How Prudently Does Relief Therapeutics Holding (VTX:RLF) Use Debt? May 05
Relief Therapeutics Announces Enrollment of First Three Patients in Proof-Of-Concept Clinical Trial of Rlf-Td011 for the Treatment of Epidermolysis Bullosa Feb 14
RELIEF THERAPEUTICS Holding SA Announces IRB Approval of Investigator-Initiated Trial Evaluating RLF-TD011 as an Adjunctive Treatment for Cutaneous T-Cell Lymphom Jan 17
Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of Olpruva™ for Patients with Urea Cycle Disorders Dec 28
Relief Therapeutics Holding AG (SWX:RLF) acquired ZYESAMI of NRx Pharmaceuticals, Inc. Dec 22
Relief Therapeutics Holding AG and NRx Pharmaceuticals, Inc. Announces Close of Definitive Settlement Agreements Dec 20 Relief Therapeutics Holding AG Appoints Jeremy Meinen as Chief Financial Officer
No independent directors Nov 16
Relief Therapeutics Holding AG Announces Six-Month Stability Data on a New Formulation of RLF-100 (Aviptadil) Nov 07
RELIEF THERAPEUTICS Holding SA Promotes Paolo Galfetti to Chief Operating Officer Oct 14
Relief Therapeutics Holding SA Announces U.S. Launch of PKU GOLIKE Oct 11
Does Relief Therapeutics Holding (VTX:RLF) Have A Healthy Balance Sheet? Oct 04
Relief Therapeutics Holding AG Announces IRB Approval and Initiation of an Investigator Initiated Trial of Nexodyn for Epidermolysis Bullosa At Ann & Robert H. Lurie Children's Hospital of Chicago Sep 22
Relief Therapeutics Holding AG has filed an IPO. Aug 24
Relief Therapeutics Holding AG and NRx Pharmaceuticals, Inc. Announce Tentative Settlement of Pending Litigation Aug 23
Relief Therapeutics Holding SA Appoints David McCullough as Head of U.S. Market Access, Effective August 22, 2022 Aug 17
RELIEF THERAPEUTICS Holding SA and Acer Therapeutics Inc. Announce That the European Commission Has Granted Orphan Drug Designation for Acer-001 in Maple Syrup Urine Disease Aug 13
Relief Therapeutics Holding Ag Announces U.S. Food and Drug Administration Accepts for Review Acer’s Resubmitted New Drug Application Aug 06 Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for ACER-001 for Treatment of UCDs
Relief Therapeutics Appoints Serene Forte, Ph.D., MPH, as Senior Vice President, Head of Genetic Medicine Jul 18
Acer Therapeutics and Relief Therapeutics Announce Update on U.S. FDA Review of New Drug Application for ACER-001 Jun 22
Relief Therapeutics Expands U.S. Commercial Team May 24
Acer Therapeutics Inc. and Relief Therapeutics Holding AG Announce Presentation of Acer-001 Data At the Genetic Metabolic Dieticians International Conference May 08
Relief Therapeutics Holding AG, Annual General Meeting, May 31, 2022 May 06
Price target decreased to CHF0.41 Apr 27
No independent directors Apr 27
Relief Therapeutics Holding AG Appoints Drew Cronin-Fine as Executive Director, Head of U.S. Marketing Apr 26
Relief Therapeutics Holding (VTX:RLF) Has Debt But No Earnings; Should You Worry? Apr 23
Acer Therapeutics Inc. and Relief Therapeutics Announce Presentation of ACER-001 Data at the Society for Inherited Metabolic Disorders Annual Meeting Apr 12
Relief Therapeutics Holding SA Files Trademark Application for RLF-100 with the U.S. Patent and Trademark Office Feb 08
Relief Therapeutics Holding AG Approves Election of Michelle Lock as New Member of the Board of Directors Jan 31
NRx Pharmaceuticals Files Counterclaim Against its Former Collaboration Partner, Relief Therapeutics Jan 13
Relief Therapeutics Reports Successful Conclusion of Patent Examination Procedure for Patent Application Entitled, 'Vasoactive Intestinal Peptide (VIP) for the Use in the Treatment of Drug-Induced Pneumonitis Dec 28
Relief Therapeutics Holding SA Announces New Safety Update on Aviptadil Dec 16
Chief Commercial Officer Christiaan L. J. Stijnen has left the company Dec 01
Relief Therapeutics Holding (VTX:RLF) Has Debt But No Earnings; Should You Worry? Sep 25
Relief Therapeutics Holding AG (SWX:RLF) completed the acquisition of APR Applied Pharma Research s.a. Jun 30
Acer Therapeutics Plans NDA Submission for Acer-001 in Third Quarter 2021 Following Pre-NDA Meeting with FDA May 26
Relief Provides Update on Progress and Plans with Acer-001 for the Treatment of Urea Cycle Disorders May 21
Relief Therapeutics Holding AG (SWX:RLF) signed binding term sheet to acquire APR Applied Pharma Research s.a. for CHF. May 05
New 90-day low: CHF0.27 Mar 11
Relief Therapeutics Successfully Demonstrated Ten-Day Accelerated Recovery from Respiratory Failure Among Critically Iii Patients with Covid-19 Feb 25
NeuroRx and Relief Therapeutics Holding AG Report Initial Phase 2b/3 Study Results Demonstrating Significant Benefit of ZYESAMI™ in Reducing Hospital Stay Among Patients with Respiratory Failure due to Critical COVID-19 Feb 10
Director has left the company Feb 10
RELIEF THERAPEUTICS Holding AG Announces Resignation of Thomaz Burckhardt as Member of the Board of Directors Feb 10
Relief Therapeutics Holding AG Affirms Initiation of Phase 2/3 Trial of Inhaled RLF-100(TM) (Aviptadil; ZYESAMI(TM)) in Severe COVID-19 Patients Feb 08
New 90-day high: CHF0.46 Feb 01
Relief Therapeutics Holding Ag and Acer Therapeutics Inc. Announces the Companies Have Signed an Option Agreement Jan 26
Relief Therapeutics Holding AG (SWX:RLF) signed a binding term sheet to acquire AdVita Lifescience GmbH for €45 million. Jan 21
We Wouldn't Rely On Relief Therapeutics Holding's (VTX:RLF) Statutory Earnings As A Guide Jan 13
NeuroRx, Inc. and Relief Therapeutics Holding AG Conclude Enrollment in Their Phase 2B/3 Trial of RLF-100™ for Critical COVID-19 with Respiratory Failure Dec 30
Relief Therapeutics Holding Ag Appoints Christiaan L.J.J. Stijnen as Chief Commercial Officer Dec 23
NeuroRx and Relief Therapeutics Meet 165 Patient Enrollment Target in Phase 2b/3 Trial of RLF-100™ for Critical COVID-19 with Respiratory Failure Dec 09
NeuroRx, Inc. and Relief Therapeutics Holding AG Announces Initial Successful Results from Expanded Access Use of RLF-100(TM) (Aviptadil) in Patients with Critical COVID-19 and Severe Comorbidity Nov 26
NeuroRx and Relief Therapeutics Announce Enrollment of 150 Patients in phase 2b/3 trial of RLF-100™ for Critical COVID-19 with Respiratory Failure Nov 14
NeuroRx, Inc. and Relief Therapeutics Holdings AG Announces Continuation of RLF-100™ Trial for Treatment of COVID-19 Respiratory Failure Nov 07
New 90-day low: CHF0.35 Nov 04 주주 수익률 RLF CH Biotechs CH 마켓 7D 2.3% -0.4% 0.6% 1Y 123.6% 89.9% 2.3%
전체 주주 수익률 보기
수익률 대 산업: RLF 지난 1년 동안 89.9 %를 반환한 Swiss Biotechs 산업을 초과했습니다.
수익률 대 시장: RLF 지난 1년 동안 2.3 %를 반환한 Swiss 시장을 초과했습니다.
가격 변동성 Is RLF's price volatile compared to industry and market? RLF volatility RLF Average Weekly Movement 26.0% Biotechs Industry Average Movement 12.8% Market Average Movement 3.3% 10% most volatile stocks in CH Market 7.5% 10% least volatile stocks in CH Market 1.6%
안정적인 주가: RLF 의 주가는 지난 3개월 동안 변동성이 심했습니다.
시간에 따른 변동성: RLF 의 주간 변동성 은 지난 1년 동안 16% 에서 26% 로 증가했습니다.
회사 소개 바이오 제약 회사인 릴리프 테라퓨틱스 홀딩 SA는 스위스, 유럽, 북미 및 국제적으로 희귀 대사성, 피부과 및 폐 질환 치료를 위한 특허로 보호되는 새로운 제품을 식별, 개발 및 상업화하는 데 주력하고 있습니다. 방사선 치료로 인한 구역 및 구토, 화학 요법으로 인한 구역 및 구토, 수술 후 구역 및 구토를 치료하는 세토필름/온디솔브, 요소 주기 장애 및 메이플 시럽뇨 질환 치료를 위한 페닐부티레이트 나트륨 올프루바, 페닐케톤뇨증 식이 관리를 위한 PKU 골라이케 등을 공급하고 있습니다. 또한 티로신혈증 치료제로 임상 3상을 완료한 타이로신혈증 치료제 'TYR GOLIKE', 코로나19 관련 급성호흡곤란증후군(ARDS) 치료제로 임상 2상을 진행 중이며 폐육종증, 체크포인트 억제제 유발 폐염, 만성 베릴리아증 치료를 위한 전임상 중인 혈관 활성 장 펩타이드(VIP) 합성체 'RLF-100'도 개발 중이다.
자세히 보기 Relief Therapeutics Holding SA 기본 사항 요약 Relief Therapeutics Holding 의 수익과 매출은 시가총액과 어떻게 비교하나요? RLF 기본 통계 시가총액 CHF 55.80m 수익(TTM ) -CHF 46.24m 수익(TTM ) CHF 8.60m
수익 및 수익 최신 수익 보고서의 주요 수익성 통계(TTM) RLF 손익 계산서(TTM ) 수익 CHF 8.60m 수익 비용 CHF 2.70m 총 이익 CHF 5.90m 기타 비용 CHF 52.13m 수익 -CHF 46.24m
주당 순이익(EPS) -3.69 총 마진 68.56% 순이익 마진 -537.79% 부채/자본 비율 0.02%
RLF 의 장기적인 성과는 어땠나요?
과거 실적 및 비교 보기
기업 분석 및 재무 데이터 현황 데이터 마지막 업데이트(UTC 시간) 기업 분석 2024/12/27 03:39 장 마감 주가 2024/12/27 00:00 수익 2024/06/30 연간 수익 2023/12/31
데이터 소스 기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.
패키지 데이터 기간 미국 소스 예시 * 회사 재무 10년 애널리스트 컨센서스 추정치 +3년 시장 가격 30년 소유권 10년 관리 10년 주요 개발 사항 10년
* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.
명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.
분석 모델 및 눈송이 이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.
Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.
산업 및 부문 메트릭 업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.
애널리스트 출처 Relief Therapeutics Holding SA 2 애널리스트 중 0 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.
분석가 교육기관 Alexandre Müller Research Dynamics Bob Pooler ValuationLAB AG
0 더 많은 분석가 보기 
